Literature DB >> 19568250

Therapy: The risk of herpes zoster: another cost of anti-TNF therapy?

Tim Bongartz, Robert Orenstein.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19568250     DOI： 10.1038/nrrheum.2009.120

Source DB:  PubMed          Journal:  Nat Rev Rheumatol        ISSN： 1759-4790            Impact factor:   20.543


× No keyword cloud information.
  9 in total

1.  Risk of serious infections and malignancies with anti-TNF antibody therapy in rheumatoid arthritis.

Authors:  Peter E Callegari; Thomas F Schaible; Jerome A Boscia
Journal:  JAMA       Date:  2006-11-08       Impact factor: 56.272

2.  Incidence of herpes zoster, 1997-2002.

Authors:  J P Mullooly; K Riedlinger; C Chun; S Weinmann; H Houston
Journal:  Epidemiol Infect       Date:  2005-04       Impact factor: 2.451

3.  Effectiveness of recommendations to prevent reactivation of latent tuberculosis infection in patients treated with tumor necrosis factor antagonists.

Authors:  Loreto Carmona; Juan J Gómez-Reino; Vicente Rodríguez-Valverde; Dolores Montero; Eliseo Pascual-Gómez; Emilio Martin Mola; Luis Carreño; Manuel Figueroa
Journal:  Arthritis Rheum       Date:  2005-06

4.  Rates and predictors of herpes zoster in patients with rheumatoid arthritis and non-inflammatory musculoskeletal disorders.

Authors:  F Wolfe; K Michaud; E F Chakravarty
Journal:  Rheumatology (Oxford)       Date:  2006-09-26       Impact factor: 7.580

Review 5.  The safety of anti-tumour necrosis factor therapy in rheumatoid arthritis.

Authors:  Johan Askling; Will Dixon
Journal:  Curr Opin Rheumatol       Date:  2008-03       Impact factor: 5.006

6.  Prevention of herpes zoster: recommendations of the Advisory Committee on Immunization Practices (ACIP).

Authors:  Rafael Harpaz; Ismael R Ortega-Sanchez; Jane F Seward
Journal:  MMWR Recomm Rep       Date:  2008-06-06

7.  Risk of herpes zoster in patients with rheumatoid arthritis treated with anti-TNF-alpha agents.

Authors:  Anja Strangfeld; Joachim Listing; Peter Herzer; Anke Liebhaber; Karin Rockwitz; Constanze Richter; Angela Zink
Journal:  JAMA       Date:  2009-02-18       Impact factor: 56.272

8.  Herpes zoster risk factors in a national cohort of veterans with rheumatoid arthritis.

Authors:  Jay R McDonald; Angelique L Zeringue; Liron Caplan; Prabha Ranganathan; Hong Xian; Thomas E Burroughs; Victoria J Fraser; Fran Cunningham; Seth A Eisen
Journal:  Clin Infect Dis       Date:  2009-05-15       Impact factor: 9.079

9.  The risk of herpes zoster in patients with rheumatoid arthritis in the United States and the United Kingdom.

Authors:  Allison L Smitten; Hyon K Choi; Marc C Hochberg; Samy Suissa; Teresa A Simon; Marcia A Testa; K Arnold Chan
Journal:  Arthritis Rheum       Date:  2007-12-15
  9 in total
  5 in total

Review 1.  Progranulin: a promising therapeutic target for rheumatoid arthritis.

Authors:  Chuan-ju Liu
Journal:  FEBS Lett       Date:  2011-05-04       Impact factor: 4.124

2.  Increased risk of herpes zoster among 108 604 patients with inflammatory bowel disease.

Authors:  M D Long; C Martin; R S Sandler; M D Kappelman
Journal:  Aliment Pharmacol Ther       Date:  2012-12-13       Impact factor: 8.171

3.  Herpes zoster is associated with prior statin use: a population-based case-control study.

Authors:  Shiu-Dong Chung; Ming-Chieh Tsai; Shih-Ping Liu; Herng-Ching Lin; Jiunn-Horng Kang
Journal:  PLoS One       Date:  2014-10-24       Impact factor: 3.240

Review 4.  B Cell Therapies, Approved and Emerging: a Review of Infectious Risk and Prevention During Use.

Authors:  Md Yuzaiful Md Yusof; Edward M Vital; Maya H Buch
Journal:  Curr Rheumatol Rep       Date:  2015-10       Impact factor: 4.592

5.  Long-term safety of rituximab in rheumatoid arthritis: 9.5-year follow-up of the global clinical trial programme with a focus on adverse events of interest in RA patients.

Authors:  Ronald F van Vollenhoven; Paul Emery; Clifton O Bingham; Edward C Keystone; Roy M Fleischmann; Daniel E Furst; Nicola Tyson; Neil Collinson; Patricia B Lehane
Journal:  Ann Rheum Dis       Date:  2012-11-07       Impact factor: 19.103
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.